Project Grant HT94252510212

This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $484,200 in funding to the Mayo Clinic to conduct a multi-disciplinary research project on gastrointestinal symptoms, especially constipation, in Parkinson's disease. The key objectives of the project are to: 1) Compare neurological, gastrointestinal, and imaging abnormalities...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $195,000 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Medical College of Wisconsin, Inc. The grant, effective from April 15, 2024 to March 31, 2026, will fund research to explore modifying the gut microbiome to enhance the effectiveness of L-DOPA therapy for Parkinson's disease. The key objectives are to investigate the impact of colonizing...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support the development of novel therapeutics to treat fecal incontinence and fecal urgency. The awardee, Dignify Therapeutics, LLC, will conduct preclinical research and development activities to advance a pipeline of investigational drugs that inhibit sensitized colorectal afferent...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $389,852 to Dignify Therapeutics, LLC to develop novel drug formulations for treating urinary incontinence and overactive bladder symptoms in the elderly. The research aims to create new intravesical (bladder-instilled) drug therapies that can provide long-term relief of these common age-related conditions by blocking the nociceptor (pain-sensing) neurons responsible for the symptoms. The...

Dignify Therapeutics, LLC was awarded a $1.88 million Project Grant from the Defense Health Agency through the Military Medical Research and Development Program to support research titled "Intrarectal Mechanoreceptor Sensitization to Induce Defecation After Spinal Injury" from September 1, 2023 to August 31, 2025. The grant will support Dignify Therapeutics' ongoing efforts to develop novel therapeutics targeting sacral spinal cord neurons involved in continence and sexual function...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to identify changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for Parkinson's disease (PD) and Alzheimer's disease related dementias (ADRD), including Lewy body dementia (LBD). The $793,535 award to Weill Medical College of Cornell University will fund...

This $318,488 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development and testing of optimized oral formulations for treating chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The award recipient, Dolor Therapeutics, LLC, will conduct feasibility studies in dogs and mice to evaluate permeation-enhanced dual therapy...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $494,040 Project Grant (CFDA 93.853) to Mark Therapeutics, Inc., a woman-owned small business in Hingham, MA. The grant supports the development of a first-in-class, disease-modifying gene therapy to treat idiopathic Parkinson's disease, the most common form affecting patients with no known genetic mutations or family history. The key objectives are to optimize and test new adeno-associated viral (AAV) candidate...

This Cooperative Agreement award for $399,174 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to investigate the relationship between Parkinson's disease and gut-brain communication. The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will contribute Parkinson's disease patients and healthy controls...

Tsrl, Inc., doing business as Therapeutic Systems Research Laboratories, was awarded a $599,240 Project Grant from the National Institutes of Health National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865). The funding will support the development of a novel microneedle patch delivery system for trospium chloride to treat overactive bladder. Trospium chloride is an anticholinergic drug currently used to...